New drug candidate AMX0035 tested in PSP patients – results awaited
Disease control
Completed
This study tested whether AMX0035 can slow down the worsening of progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. 139 adults aged 40-80 with early-stage PSP took either the drug or a placebo for several months. The main goal was to se…
Phase: PHASE2, PHASE3 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC